Dual blockade of protease-activated receptor 1 and 2 additively ameliorates diabetic kidney disease.


Journal

American journal of physiology. Renal physiology
ISSN: 1522-1466
Titre abrégé: Am J Physiol Renal Physiol
Pays: United States
ID NLM: 100901990

Informations de publication

Date de publication:
01 05 2020
Historique:
pubmed: 24 3 2020
medline: 15 7 2020
entrez: 24 3 2020
Statut: ppublish

Résumé

Protease-activated receptors (PARs) are coagulation protease targets, and they increase expression of inflammatory cytokines and chemokines in various diseases. Of all PARs, previous reports have shown that PAR1 or PAR2 inhibition is protective against diabetic glomerular injury. However, how PAR1 and PAR2 cooperatively contribute to diabetic kidney disease (DKD) pathogenesis and whether dual blockade of PARs is more effective in DKD remain elusive. To address this issue, male type I diabetic Akita mice heterozygous for endothelial nitric oxide synthase were used as a model of DKD. Mice (4 mo old) were divided into four treatment groups and administered vehicle, PAR1 antagonist (E5555, 60 mg·kg

Identifiants

pubmed: 32200667
doi: 10.1152/ajprenal.00595.2019
pmc: PMC7294339
doi:

Substances chimiques

Collagen Type IV 0
Cytokines 0
E 5555 0
F2RL1 protein, human 0
F2rl1 protein, mouse 0
H-Phe-Ser-Leu-Leu-Arg-Tyr-NH2 0
Imines 0
Inflammation Mediators 0
Oligopeptides 0
Pyridines 0
Receptor, PAR-1 0
Receptor, PAR-2 0
Nitric Oxide Synthase Type III EC 1.14.13.39
Nos3 protein, mouse EC 1.14.13.39

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

F1067-F1073

Références

Am J Physiol Renal Physiol. 2019 Apr 1;316(4):F654-F659
pubmed: 30672316
Virchows Arch. 2001 Feb;438(2):129-35
pubmed: 11253114
Sci Rep. 2016 Sep 13;6:33030
pubmed: 27618774
Front Endocrinol (Lausanne). 2014 May 13;5:67
pubmed: 24860547
Eur J Pharmacol. 2011 Sep;666(1-3):158-64
pubmed: 21635884
Thromb Res. 2016 Jun;142:44-51
pubmed: 27131284
Thromb Haemost. 2014 Nov;112(5):876-82
pubmed: 24990498
Proc Natl Acad Sci U S A. 2011 Feb 1;108(5):2070-5
pubmed: 21245338
J Invest Dermatol. 2002 Feb;118(2):380-5
pubmed: 11841560
Nat Rev Nephrol. 2011 Jun;7(6):327-40
pubmed: 21537349
Oncotarget. 2018 Apr 24;9(31):21655-21662
pubmed: 29774092
FASEB J. 2019 Oct;33(10):10966-10972
pubmed: 31287960
Proc Natl Acad Sci U S A. 1983 Jun;80(12):3734-7
pubmed: 6407019
JAMA. 2016 Aug 9;316(6):602-10
pubmed: 27532915
N Engl J Med. 2012 Jan 5;366(1):20-33
pubmed: 22077816
Eur Heart J. 2010 Nov;31(21):2601-13
pubmed: 20805115
J Cell Mol Med. 2019 Feb;23(2):1268-1279
pubmed: 30485646
Arterioscler Thromb Vasc Biol. 2016 Aug;36(8):1525-33
pubmed: 27283743
J Clin Invest. 2014 Jun;124(6):2333-40
pubmed: 24892707
ACS Med Chem Lett. 2018 Dec 03;10(1):121-126
pubmed: 30655958
Biochem Biophys Res Commun. 2017 Jan 29;483(1):547-552
pubmed: 28025140
Nature. 2017 May 4;545(7652):112-115
pubmed: 28445455
J Am Soc Nephrol. 2016 Jun;27(6):1635-49
pubmed: 26567242
Basic Res Cardiol. 2011 Jan;106(1):111-23
pubmed: 20972877
J Leukoc Biol. 2008 Jul;84(1):215-23
pubmed: 18436581
Semin Immunopathol. 2012 Jan;34(1):133-49
pubmed: 21971685
Front Pharmacol. 2017 Nov 07;8:798
pubmed: 29163178
Kidney Int. 2007 Feb;71(3):266-71
pubmed: 17149371
Sci Rep. 2019 Feb 27;9(1):2986
pubmed: 30814628
J Med Chem. 2013 Oct 10;56(19):7477-97
pubmed: 23895492
Clin J Am Soc Nephrol. 2017 Aug 7;12(8):1366-1373
pubmed: 28280116

Auteurs

Shohei Mitsui (S)

Division of Clinical Pharmacology and Therapeutics, Tohoku University Graduate School of Pharmaceutical Sciences and Faculty of Pharmaceutical Sciences, Sendai, Japan.

Yuji Oe (Y)

Department of Community Medical Support, Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Division of Nephrology, Endocrinology and Vascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.

Akiyo Sekimoto (A)

Division of Clinical Pharmacology and Therapeutics, Tohoku University Graduate School of Pharmaceutical Sciences and Faculty of Pharmaceutical Sciences, Sendai, Japan.

Emiko Sato (E)

Division of Clinical Pharmacology and Therapeutics, Tohoku University Graduate School of Pharmaceutical Sciences and Faculty of Pharmaceutical Sciences, Sendai, Japan.
Division of Nephrology, Endocrinology and Vascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.

Yamato Hashizume (Y)

Division of Clinical Pharmacology and Therapeutics, Tohoku University Graduate School of Pharmaceutical Sciences and Faculty of Pharmaceutical Sciences, Sendai, Japan.

Shu Yamakage (S)

Division of Nephrology, Endocrinology and Vascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.

Satoshi Kumakura (S)

Division of Nephrology, Endocrinology and Vascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.

Hiroshi Sato (H)

Division of Clinical Pharmacology and Therapeutics, Tohoku University Graduate School of Pharmaceutical Sciences and Faculty of Pharmaceutical Sciences, Sendai, Japan.
Division of Nephrology, Endocrinology and Vascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.

Sadayoshi Ito (S)

Division of Nephrology, Endocrinology and Vascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.

Nobuyuki Takahashi (N)

Division of Clinical Pharmacology and Therapeutics, Tohoku University Graduate School of Pharmaceutical Sciences and Faculty of Pharmaceutical Sciences, Sendai, Japan.
Division of Nephrology, Endocrinology and Vascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH